> Details

Oubaya, Nadia; Soubeyran, Pierre; Reinald, Nicoleta; Fonck, Marianne; Allain, Mylène; Zebachi, Sonia; Heitz, Damien; Laurent, Marie; Delattre, Cécile; Caillet, Philippe; Dauba, Jérôme; Bastuji-Garin, Sylvie; Albrand, Gilles; Bringuier, Michael; Rainfray, Muriel; Brain, Etienne; Grellety, Thomas; Paillaud, Elena; Mathoulin-Pélissier, Simone; Bellera, Carine; Canouï-Poitrine, Florence

Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts
  • Contributor: Oubaya, Nadia; Soubeyran, Pierre; Reinald, Nicoleta; Fonck, Marianne; Allain, Mylène; Zebachi, Sonia; Heitz, Damien; Laurent, Marie; Delattre, Cécile; Caillet, Philippe; Dauba, Jérôme; Bastuji-Garin, Sylvie; Albrand, Gilles; Bringuier, Michael; Rainfray, Muriel; Brain, Etienne; Grellety, Thomas; Paillaud, Elena; Mathoulin-Pélissier, Simone; Bellera, Carine; Canouï-Poitrine, Florence
  • Published: MDPI AG, 2021
  • Published in: Cancers, 13 (2021) 24, Seite 6154
  • Language: English
  • DOI: 10.3390/cancers13246154
  • ISSN: 2072-6694
  • Origination:
  • Footnote:
  • Description: Background: The prognostic assessment of older cancer patients is complicated by their heterogeneity. We aimed to assess the prognostic value of routine inflammatory biomarkers. Methods: A pooled analysis of prospective multicenter cohorts of cancer patients aged ≥70 was performed. We measured CRP and albumin, and calculated Glasgow Prognostic Score (GPS) and CRP/albumin ratio. The GPS has three levels (0 = CRP ≤ 10 mg/L, albumin ≥ 35 g/L, i.e., normal values; 1 = one abnormal value; 2 = two abnormal values). One-year mortality was assessed using Cox models. Discriminative power was assessed using Harrell’s C index (C) and net reclassification improvement (NRI). Results: Overall, 1800 patients were analyzed (mean age: 79 ± 6; males: 62%; metastases: 38%). The GPS and CRP/albumin ratio were independently associated with mortality in patients not at risk of frailty (hazard ratio [95% confidence interval] = 4.48 [2.03–9.89] for GPS1, 11.64 [4.54–29.81] for GPS2, and 7.15 [3.22–15.90] for CRP/albumin ratio > 0.215) and in patients at risk of frailty (2.45 [1.79–3.34] for GPS1, 3.97 [2.93–5.37] for GPS2, and 2.81 [2.17–3.65] for CRP/albumin ratio > 0.215). The discriminative power of the baseline clinical model (C = 0.82 [0.80–0.83]) was increased by adding GPS (C = 0.84 [0.82–0.85]; NRI events (NRI+) = 10% [2–16]) and CRP/albumin ratio (C = 0.83 [0.82–0.85]; NRI+ = 14% [2–17]). Conclusions: Routine inflammatory biomarkers add prognostic value to clinical factors in older cancer patients.
  • Access State: Open Access